Pfizer stopped the production of biosimilars in China, and the former "golden track" no longer exists?

On February 18, CDE issued the Technical Guidelines for the Evaluation of Similarity of Biologicalsimilars and the Extrapolation of Indications
.
In this regard, industry insiders commented: The "consistency evaluation" of biosimilar drugs is coming and will also be included in centralized procurement in the future
.

Previously, biopharmaceuticals were once known as the "forbidden zone for volume procurement", which could avoid the price impact of centralized procurement
.
In addition, the research and development cost of biosimilar drugs is lower than that of original innovative drugs, and many domestic and foreign companies are more enthusiastic about biosimilar drugs
.

Now that the "forbidden zone" is broken, this will naturally bring down the enthusiasm of the company
.

As far as adalimumab is concerned, the original price of the original research drug Xiu Meile is 7586 yuan/piece (40ml), the medical insurance payment price is 1,290 yuan/piece, and Biotech’s Gelli is priced at 1,160 yuan/piece, and Hisun Pharmaceuticals The price of An Jianning and Cinda Bio's Su Lixin are both 1150 yuan/piece
.
The Handa of Fuhong Hanli is far 899 yuan/piece
.

If we refer to the 75% average drop in the centralized procurement of chemical drugs, the price of biosimilar drugs after the centralized procurement is expected to drop to less than 1,000 yuan
.
This is undoubtedly a head-on blow to companies including Pfizer that have not yet entered the market
.